Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

• To evaluate the efficacy and toxicity of concurrent chemoradiotherapy combined with sodium glycididazole in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy, and to explore sodium glycididazole as a new way to inhibit the occurrence of radiation esophagitis and reduce the occurrence of radiation pneumonitis and lymphopenia.
• To evaluate the sensitization effect of sodium glycididazole in the anti-tumor activity during concurrent chemoradiotherapy, as well as the changes in the anti-tumor immune response in peripheral blood, in order to screen out the dominant population and the predictive biomarkers with fewer related toxic and side effects.
• By exploring the correlation between the expression level of NLRP3 inflammasome activation related molecules and imaging changes in peripheral blood after radiotherapy and the toxicity of radiotherapy and chemotherapy, a risk model for predicting radiation esophagitis after concurrent radiotherapy and chemotherapy for non-small cell lung cancer was further constructed.

Inclusion criteria

• Patients must have histologically or cytologically confirmed non-small cell lung cancer.
• Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
• ECOG PS 0-2
• Adequate organ and bone marrow function.

Exclusion criteria

• History of previous radiotherapy.
• The previous immune-related pneumonitis ≥ grade 2.
• Local lesions require surgery.
• History of another primary malignancy.
• History of active primary immunodeficiency.
• Histological findings showed mixed small cell lung cancer and non-small cell lung cancer.
• For any unmitigated toxicity during pre-study chemoradiotherapy.